MET and non-small cell lung carcinoma: ,67 Selective MET-TKIs such as savolitinib, capmatinib, and tepotinib have emerged in recent years and showed considerable progress in patients with METex14 mutations or MET amplification.68, 69, 70 Based on the results of its phase II clinical trial, which reported an ORR of 49.2% and an acceptable safety profile, savolitinib was approved on June 22, 2021, by the NMPA as the first MET-TKI intended for the treatment of patients with locally advanced and metastatic METex14-positive NSCLC in China.68